There are significant obstacles facing vaccines in that they: Are slow to develop and manufacture; Often have sub-optimal levels, broadness and duration of protection; Use archaic growth systems and/or potentially toxic chemicals; Rely on exotic and unproven methods; Have limited flexibility/coverage; Require challenging storage conditions and distribution channels; Face skepticism in general population.

The SolaVAX™ method employs the use of a photochemical (riboflavin/vitamin B2) in combination with UV light in the UVA and UVB wavelength regions to carry out specific nucleic acid alterations in pathogens, rendering them non-infective while maintaining authentic antigen presentation.